---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-020345"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:34:59.710317+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vericel Q2 revenue $37M, net loss $9M; maintains FY guidance, NexoBrid BLA accepted with PDUFA Jan 2023

## Summary
- Total net revenue $37.0M (MACI $28.6M +8% YoY, Epicel $8.2M, NexoBrid $0.2M); net loss $9.0M ($0.19/sh).
- Non-GAAP adjusted EBITDA $2.8M (7% margin); operating cash flow $3.1M; cash & investments $131M, no debt.
- FY 2022 guidance reaffirmed: total revenue $178-189M, MACI $132-141M, gross margin ~69%, adj. EBITDA margin ~21%.
- NexoBrid BLA resubmission accepted by FDA; PDUFA date Jan 1, 2023.
- Entered $150M revolving credit facility with J.P. Morgan-led syndicate; issued inaugural ESG report.

## SEC filing metadata
- accession: 0001628280-22-020345
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828022020345/0001628280-22-020345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828022020345/vcel-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-020345
- JSON: https://secwatch.observer/filing/0001628280-22-020345.json
- Plain text: https://secwatch.observer/filing/0001628280-22-020345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.